Aptevo Therapeutics Stock Alpha and Beta Analysis
| APVO Stock | USD 10.01 0.81 8.80% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aptevo Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aptevo Therapeutics over a specified time horizon. Remember, high Aptevo Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aptevo Therapeutics' market risk premium analysis include:
Beta 0.17 | Alpha 0.2 | Risk 12.59 | Sharpe Ratio 0.0256 | Expected Return 0.32 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aptevo |
Aptevo Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aptevo Therapeutics market risk premium is the additional return an investor will receive from holding Aptevo Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aptevo Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aptevo Therapeutics' performance over market.| α | 0.20 | β | 0.17 |
Aptevo Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Aptevo Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Aptevo Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Aptevo Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Aptevo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aptevo Therapeutics shares will generate the highest return on investment. By understating and applying Aptevo Therapeutics stock market price indicators, traders can identify Aptevo Therapeutics position entry and exit signals to maximize returns.
Aptevo Therapeutics Return and Market Media
The median price of Aptevo Therapeutics for the period between Thu, Sep 12, 2024 and Wed, Dec 11, 2024 is 9.07 with a coefficient of variation of 27.36. The daily time series for the period is distributed with a sample standard deviation of 2.43, arithmetic mean of 8.88, and mean deviation of 2.03. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Aptevo Therapeutics Now Covered by Analysts at StockNews.com | 10/10/2024 |
2 | Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Type... | 10/29/2024 |
3 | Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB | 10/31/2024 |
4 | Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update | 11/07/2024 |
5 | Armistice Capital, LLCs Strategic Acquisition of Aptevo Therapeutics Inc Shares | 11/15/2024 |
6 | First Patient Dosed in Aptevos Ongoing RAINIER Trial Achieves 90 percent Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall E... | 11/20/2024 |
7 | Aptevo Highlights the Potential of the Companys Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance... | 11/22/2024 |
8 | Proving the Concept Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation | 11/26/2024 |
9 | Aptevo Therapeutics announces 1-for-37 reverse stock split APVO | 11/29/2024 |
10 | Aptevo Therapeutics executes reverse stock split | 12/04/2024 |
About Aptevo Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aptevo or other stocks. Alpha measures the amount that position in Aptevo Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 108.8 | 293.03 | 263.73 | 276.91 | PTB Ratio | 1.1K | 24.45 | 6.7 | 6.37 |
Aptevo Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Aptevo Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aptevo Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aptevo Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aptevo Therapeutics. Please utilize our Beneish M Score to check the likelihood of Aptevo Therapeutics' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aptevo Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Aptevo Therapeutics Backtesting, Aptevo Therapeutics Valuation, Aptevo Therapeutics Correlation, Aptevo Therapeutics Hype Analysis, Aptevo Therapeutics Volatility, Aptevo Therapeutics History and analyze Aptevo Therapeutics Performance. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Aptevo Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.